BR112021020148A2 - Combinações de anticorpos anti-ildr2 e antagonistas pd-1 - Google Patents
Combinações de anticorpos anti-ildr2 e antagonistas pd-1Info
- Publication number
- BR112021020148A2 BR112021020148A2 BR112021020148A BR112021020148A BR112021020148A2 BR 112021020148 A2 BR112021020148 A2 BR 112021020148A2 BR 112021020148 A BR112021020148 A BR 112021020148A BR 112021020148 A BR112021020148 A BR 112021020148A BR 112021020148 A2 BR112021020148 A2 BR 112021020148A2
- Authority
- BR
- Brazil
- Prior art keywords
- ildr2
- antagonists
- antibodies
- combinations
- antibody
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 229940124060 PD-1 antagonist Drugs 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
combinações de anticorpos antiildr2 e antagonistas pd-1. a presente invenção refere-se a um anticorpo anti-ildr2, um fragmento ou derivado do mesmo, um formato de anticorpo modificado, ou uma mimética de anticorpo, para uso em combinação com um antagonista pd-1 no tratamento do câncer. outros aspectos da presente invenção referem-se a uma combinação compreendendo um anticorpo anti-ildr2 e um antagonista pd-1 e o uso de tal combinação como um medicamento, bem como métodos de tratamento ou profilaxia de um câncer em um indivíduo, compreendendo administrar ao dito indivíduo uma quantidade terapeuticamente eficaz dos anticorpos como descrito aqui descrito. além disso, a presente invenção refere-se a um kit compreendendo anticorpos anti-ildr2 e antagonistas pd-1 e, opcionalmente, um ou mais outros agentes farmacêuticos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832320P | 2019-04-11 | 2019-04-11 | |
| PCT/EP2020/059745 WO2020207961A1 (en) | 2019-04-11 | 2020-04-06 | Combinations of anti-ildr2 antibodies and pd-1 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021020148A2 true BR112021020148A2 (pt) | 2021-12-21 |
Family
ID=70224379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021020148A BR112021020148A2 (pt) | 2019-04-11 | 2020-04-06 | Combinações de anticorpos anti-ildr2 e antagonistas pd-1 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220169736A1 (pt) |
| EP (1) | EP3952910A1 (pt) |
| JP (1) | JP2022528472A (pt) |
| KR (1) | KR20210151808A (pt) |
| CN (1) | CN113645999A (pt) |
| AR (1) | AR118621A1 (pt) |
| AU (1) | AU2020271352A1 (pt) |
| BR (1) | BR112021020148A2 (pt) |
| CA (1) | CA3136510A1 (pt) |
| IL (1) | IL287093A (pt) |
| MX (1) | MX2021012406A (pt) |
| PE (1) | PE20212271A1 (pt) |
| SG (1) | SG11202109623WA (pt) |
| TW (1) | TW202104275A (pt) |
| WO (1) | WO2020207961A1 (pt) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
| LT2769729T (lt) * | 2007-09-04 | 2019-05-10 | Compugen Ltd. | Polipeptidai ir polinukleotidai ir jų panaudojimas kaip vaistų taikinio vaistų ir biologinių preparatų gamybai |
| KR20140126357A (ko) * | 2012-02-01 | 2014-10-30 | 컴퓨젠 엘티디. | C1orf32 항체 및 이의 암 치료를 위한 용도 |
| KR20200096223A (ko) * | 2017-11-30 | 2020-08-11 | 바이엘 악티엔게젤샤프트 | Ildr2 길항제 및 그의 조합물 |
-
2020
- 2020-04-06 PE PE2021001680A patent/PE20212271A1/es unknown
- 2020-04-06 KR KR1020217032165A patent/KR20210151808A/ko unknown
- 2020-04-06 CN CN202080027714.5A patent/CN113645999A/zh active Pending
- 2020-04-06 JP JP2021560557A patent/JP2022528472A/ja active Pending
- 2020-04-06 SG SG11202109623W patent/SG11202109623WA/en unknown
- 2020-04-06 EP EP20717633.0A patent/EP3952910A1/en active Pending
- 2020-04-06 WO PCT/EP2020/059745 patent/WO2020207961A1/en active Application Filing
- 2020-04-06 AU AU2020271352A patent/AU2020271352A1/en active Pending
- 2020-04-06 MX MX2021012406A patent/MX2021012406A/es unknown
- 2020-04-06 BR BR112021020148A patent/BR112021020148A2/pt not_active Application Discontinuation
- 2020-04-06 US US17/594,269 patent/US20220169736A1/en active Pending
- 2020-04-06 CA CA3136510A patent/CA3136510A1/en active Pending
- 2020-04-08 AR ARP200100985A patent/AR118621A1/es unknown
- 2020-04-09 TW TW109111937A patent/TW202104275A/zh unknown
-
2021
- 2021-10-07 IL IL287093A patent/IL287093A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202109623WA (en) | 2021-10-28 |
| PE20212271A1 (es) | 2021-11-30 |
| TW202104275A (zh) | 2021-02-01 |
| KR20210151808A (ko) | 2021-12-14 |
| CA3136510A1 (en) | 2020-10-15 |
| WO2020207961A1 (en) | 2020-10-15 |
| AU2020271352A8 (en) | 2022-04-07 |
| JP2022528472A (ja) | 2022-06-10 |
| MX2021012406A (es) | 2022-01-19 |
| EP3952910A1 (en) | 2022-02-16 |
| IL287093A (en) | 2021-12-01 |
| US20220169736A1 (en) | 2022-06-02 |
| AU2020271352A1 (en) | 2021-10-07 |
| CN113645999A (zh) | 2021-11-12 |
| AR118621A1 (es) | 2021-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125144T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| PH12018500642A1 (en) | Anti-garp antibody | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| BR112016030541A2 (pt) | métodos para o tratamento de infecções fúngicas | |
| BR112017021688A2 (pt) | composições compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo | |
| BR112016012506A2 (pt) | Combinações farmacêuticas, seus usos, e uso de um portador de dados | |
| BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
| BR112017008042A2 (pt) | métodos e composições para dosagem em terapia de célula adotiva | |
| BR112015021371A2 (pt) | uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares | |
| BR112018072681A2 (pt) | anticorpos anti-il-1r3 humanizados | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112015011171A2 (pt) | compostos de pirrolopirimidina como inibidores da quinase | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| BR112015026247A8 (pt) | composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| BR112015026238A8 (pt) | composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit | |
| BR112017019343A2 (pt) | uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112015022650A2 (pt) | inibidores de cinase induzível por sal macrocíclico | |
| BR112021021195A2 (pt) | Métodos para tratamento ou prevenção da asma pela administração de um antagonista de il-33 | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| EA201690321A1 (ru) | Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей | |
| AR082353A1 (es) | Ligando ox40 y de linfopoyetina del estroma timico (tslp) en el cancer | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| BR112019011350A2 (pt) | terapia de combinação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |